Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes

Troy C. Lund, Weston P. Miller, Ai Yin Liao, Jakub Tolar, Ryan Shanley, Marzia Pasquali, Nicole Sando, Brian W. Bigger, Lynda E. Polgreen, Paul J. Orchard

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme replacement therapy (IV-ERT) post transplantation. Ten children with MPS-IH and ≥2 years from successful HCT underwent IV-ERT for 2 years’ duration. Patients were monitored for anti-drug antibody (ADA) development, including inhibitory capacity and changes in urinary excretion of glycosaminoglycans (uGAG). Three patients demonstrated low-level ADA at baseline, though all children tolerated IV-ERT well. Eight patients developed ADA over the 2-year study, with 3 (38%) meeting criteria for an inhibitory ADA response. The aggregate cohort experienced a reduction in uGAG from baseline to study end, which was enhanced in children with low or no ADA response. Conversely, children with inhibitory ADA showed increase in uGAG over time. IV-ERT in previously transplanted children with MPS-IH appears safe and can reduce uGAG, although this is reversed by the presence of inhibitory ADA. These data show a biochemical change after initiation of post-HCT IV-ERT, but the occurrence of ADA and inhibitory antibodies are a concern and should be monitored in future efficacy trials. This trial was registered at www.clinicaltrials.gov, NCT01173016, 07/30/2010.

Original languageEnglish (US)
Article number14105
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Mucopolysaccharidosis I
Anti-Idiotypic Antibodies
Enzyme Replacement Therapy
Transplants
Glycosaminoglycans
Pharmaceutical Preparations
Cell Transplantation
Antibody Formation
Survivors
Transplantation
Safety
Antibodies

PubMed: MeSH publication types

  • Journal Article

Cite this

Post-transplant laronidase augmentation for children with Hurler syndrome : biochemical outcomes. / Lund, Troy C.; Miller, Weston P.; Liao, Ai Yin; Tolar, Jakub; Shanley, Ryan; Pasquali, Marzia; Sando, Nicole; Bigger, Brian W.; Polgreen, Lynda E.; Orchard, Paul J.

In: Scientific reports, Vol. 9, No. 1, 14105, 01.12.2019.

Research output: Contribution to journalArticle

Lund, Troy C. ; Miller, Weston P. ; Liao, Ai Yin ; Tolar, Jakub ; Shanley, Ryan ; Pasquali, Marzia ; Sando, Nicole ; Bigger, Brian W. ; Polgreen, Lynda E. ; Orchard, Paul J. / Post-transplant laronidase augmentation for children with Hurler syndrome : biochemical outcomes. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{d43fda78b9a84ed187a60d7c70e5fe83,
title = "Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme replacement therapy (IV-ERT) post transplantation. Ten children with MPS-IH and ≥2 years from successful HCT underwent IV-ERT for 2 years’ duration. Patients were monitored for anti-drug antibody (ADA) development, including inhibitory capacity and changes in urinary excretion of glycosaminoglycans (uGAG). Three patients demonstrated low-level ADA at baseline, though all children tolerated IV-ERT well. Eight patients developed ADA over the 2-year study, with 3 (38{\%}) meeting criteria for an inhibitory ADA response. The aggregate cohort experienced a reduction in uGAG from baseline to study end, which was enhanced in children with low or no ADA response. Conversely, children with inhibitory ADA showed increase in uGAG over time. IV-ERT in previously transplanted children with MPS-IH appears safe and can reduce uGAG, although this is reversed by the presence of inhibitory ADA. These data show a biochemical change after initiation of post-HCT IV-ERT, but the occurrence of ADA and inhibitory antibodies are a concern and should be monitored in future efficacy trials. This trial was registered at www.clinicaltrials.gov, NCT01173016, 07/30/2010.",
author = "Lund, {Troy C.} and Miller, {Weston P.} and Liao, {Ai Yin} and Jakub Tolar and Ryan Shanley and Marzia Pasquali and Nicole Sando and Bigger, {Brian W.} and Polgreen, {Lynda E.} and Orchard, {Paul J.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-50595-1",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Post-transplant laronidase augmentation for children with Hurler syndrome

T2 - biochemical outcomes

AU - Lund, Troy C.

AU - Miller, Weston P.

AU - Liao, Ai Yin

AU - Tolar, Jakub

AU - Shanley, Ryan

AU - Pasquali, Marzia

AU - Sando, Nicole

AU - Bigger, Brian W.

AU - Polgreen, Lynda E.

AU - Orchard, Paul J.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme replacement therapy (IV-ERT) post transplantation. Ten children with MPS-IH and ≥2 years from successful HCT underwent IV-ERT for 2 years’ duration. Patients were monitored for anti-drug antibody (ADA) development, including inhibitory capacity and changes in urinary excretion of glycosaminoglycans (uGAG). Three patients demonstrated low-level ADA at baseline, though all children tolerated IV-ERT well. Eight patients developed ADA over the 2-year study, with 3 (38%) meeting criteria for an inhibitory ADA response. The aggregate cohort experienced a reduction in uGAG from baseline to study end, which was enhanced in children with low or no ADA response. Conversely, children with inhibitory ADA showed increase in uGAG over time. IV-ERT in previously transplanted children with MPS-IH appears safe and can reduce uGAG, although this is reversed by the presence of inhibitory ADA. These data show a biochemical change after initiation of post-HCT IV-ERT, but the occurrence of ADA and inhibitory antibodies are a concern and should be monitored in future efficacy trials. This trial was registered at www.clinicaltrials.gov, NCT01173016, 07/30/2010.

AB - Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme replacement therapy (IV-ERT) post transplantation. Ten children with MPS-IH and ≥2 years from successful HCT underwent IV-ERT for 2 years’ duration. Patients were monitored for anti-drug antibody (ADA) development, including inhibitory capacity and changes in urinary excretion of glycosaminoglycans (uGAG). Three patients demonstrated low-level ADA at baseline, though all children tolerated IV-ERT well. Eight patients developed ADA over the 2-year study, with 3 (38%) meeting criteria for an inhibitory ADA response. The aggregate cohort experienced a reduction in uGAG from baseline to study end, which was enhanced in children with low or no ADA response. Conversely, children with inhibitory ADA showed increase in uGAG over time. IV-ERT in previously transplanted children with MPS-IH appears safe and can reduce uGAG, although this is reversed by the presence of inhibitory ADA. These data show a biochemical change after initiation of post-HCT IV-ERT, but the occurrence of ADA and inhibitory antibodies are a concern and should be monitored in future efficacy trials. This trial was registered at www.clinicaltrials.gov, NCT01173016, 07/30/2010.

UR - http://www.scopus.com/inward/record.url?scp=85072847883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072847883&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-50595-1

DO - 10.1038/s41598-019-50595-1

M3 - Article

C2 - 31575939

AN - SCOPUS:85072847883

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 14105

ER -